Tolebrutinib

Tolebrutinib (brand name Cenrifki) is Sanofi's oral, brain-penetrant, covalent BTK inhibitor developed for multiple sclerosis. The Phase 3 program produced a split readout: HERCULES hit its endpoint in non-relapsing secondary progressive MS (nrSPMS), an indication with no approved therapies, while GEMINI 1 and GEMINI 2 (relapsing MS) missed on annualized relapse rate versus teriflunomide, and PERSEUS (primary progressive MS) missed on 6-month confirmed disability progression [1][2][6][7][15]. The FDA issued a Complete Response Letter in December 2025 citing severe drug-induced liver injury risk, uncertain benefit in the intended population, and no clearly identified favorable benefit-risk subgroup [3]. The European Commission approved Cenrifki on June 23, 2026 for nrSPMS, making it the first EU-approved therapy specifically targeting disability progression in this population [4][16]. Sanofi's 2024 net sales were €41.1B (approximately $44.5B at 2024 average EUR/USD) per the 2024 Form 20-F [5], giving the program financial cover through the FDA response cycle. The investor question now narrows to US approvability given the CRL specifics, not overall program viability.

Novel compound (SAR442168/PRN2246), originally developed by Principia Biopharma and acquired by Sanofi in 2020. The Phase 3 program spans three MS populations: HERCULES the sole positive registration study (nrSPMS, n=1,131), GEMINI 1 (NCT04410978, n=974) and GEMINI 2 (NCT04410991) negative versus teriflunomide in relapsing MS, and PERSEUS negative versus placebo in primary progressive MS [1][6][7][15][17]. FDA granted breakthrough therapy designation for nrSPMS based on the HERCULES result, but the December 2025 Complete Response Letter identified four specific concerns: (1) serious risk of severe including fatal drug-induced liver injury, (2) uncertainties about benefit in disease subpopulations, (3) insufficient evidence of effect on disability accumulation independent of relapse activity, and (4) no study population identified with a favorable benefit-risk profile [3]. FDA cited six Hy's Law cases across the Phase 3 program of roughly 2,700 patients, including one death following liver transplant [3]. The European Commission approved Cenrifki (tolebrutinib) on June 23, 2026 following the April 2026 CHMP positive opinion, making it the first EU therapy specifically indicated for disability progression in nrSPMS [4][16]. The long-term safety extension NCT06372145 continues to run across all three MS subtypes with roughly 2,500 participants, with primary endpoints focused on adverse events and adverse events of special interest, a design that reads as regulator-facing follow-up on the hepatic safety concerns that paused enrollment in 2022 [8]. Sanofi has stated it remains in dialogue with FDA to identify a population where benefit outweighs DILI risk but has not publicly committed to a specific resubmission date [3].

BTK (Bruton's tyrosine kinase) is an enzyme inside B cells and microglia, the brain's resident immune cells. In B cells, BTK relays signals from the B-cell receptor that lead to activation, antibody production, and cytokine release [9]. In microglia, BTK amplifies chronic inflammatory activity thought to drive slow neurological damage even when acute relapses are absent [10]. The current model of progressive MS attributes ongoing disability accumulation to this smoldering, compartmentalized inflammation inside the central nervous system, distinct from the peripheral immune attacks that anti-CD20 antibodies like ocrelizumab already control well. Tolebrutinib is designed to cross the blood-brain barrier at concentrations sufficient to block microglial BTK. Peripheral BTK inhibitors approved for B-cell cancers (ibrutinib, acalabrutinib, zanubrutinib) do not penetrate the CNS at meaningful concentrations. Genetic validation for BTK biology is strong: patients with loss-of-function BTK mutations have X-linked agammaglobulinemia, a rare inherited disorder in which B cells fail to develop and patients cannot produce antibodies, leaving them severely immunodeficient. That disease is the natural experiment proving BTK is essential for B-cell development. BTK inhibitors are also established therapies in B-cell cancers like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The progressive MS thesis, however, rests specifically on brain penetration plus microglial activity, which is harder to prove clinically [10]. The HERCULES positive result in nrSPMS provides the first prospective Phase 3 evidence that CNS-penetrant BTK inhibition slows progression when peripheral inflammation is minimal, supporting the microglia hypothesis. GEMINI 1/2 missing on relapse rate versus teriflunomide, while showing a disability progression signal, aligns with recent analyses arguing that BTK inhibitors uncouple relapse biology from progression biology [11].

Three Phase 3 studies ran in parallel. GEMINI 1 (NCT04410978, n=974) and GEMINI 2 (NCT04410991) compared tolebrutinib 60 mg daily to teriflunomide 14 mg in relapsing MS, primary endpoint annualized relapse rate [6][17]. Both missed the primary endpoint but showed a favorable trend on confirmed disability worsening in pooled analysis, which has kept interest in the disability story alive. PERSEUS (NCT04458051, n=767) tested tolebrutinib against placebo in primary progressive MS with 6-month composite confirmed disability progression as primary, and missed [7]. HERCULES (NCT04411641, n=1,131 patients with EDSS 3.0 to 6.5 and recent documented progression) tested tolebrutinib versus placebo in nrSPMS with 6-month confirmed disability progression as primary endpoint and hit with a hazard ratio of 0.69 (95% CI 0.55 to 0.88, p=0.003), corresponding to a 31% relative reduction; the raw event rates were 22.6% on tolebrutinib versus 30.7% on placebo [1][15]. The confidence interval excludes 1.0 with room to spare and the p-value is well below conventional thresholds, so the effect is statistically robust rather than fragile. NCT06372145 is the ongoing long-term safety extension across all three populations (roughly 2,500 participants, active but not recruiting), with primary endpoints centered on adverse events and adverse events of special interest [8]. The design choice of a composite disability endpoint had precedent in progressive MS trials, but the negative PERSEUS result complicates cross-trial interpretation of the disability signal. The mid-2022 enrollment pause after cases of drug-induced liver injury required protocol amendments to add intensified liver monitoring [13], which has since become part of standard trial procedure. Endpoint selection was defensible; the issue was that the drug performed differently across MS subtypes, which is what the microglia hypothesis would actually predict.

Our model estimates a 65% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by strong earlier-phase results, larger-than-typical enrollment for this phase, a non-randomized design, and its light or open-label blinding. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Hepatic safety is the dominant concern and the reason for the CRL. Sanofi paused enrollment across the Phase 3 program in mid-2022 after cases of drug-induced liver injury, some severe [13]. The program resumed under intensified liver monitoring, and a hepatotoxicity mechanism study using primary human liver spheroids has helped characterize the biology [14]. The FDA CRL cited six Hy's Law cases in a program of roughly 2,700 patients, including one death after liver transplant, and framed severe DILI as unresolved [3]. This is likely to translate into REMS requirements (Risk Evaluation and Mitigation Strategy, an FDA-mandated safety monitoring program with prescriber, patient, and pharmacy obligations) at minimum, and potentially a narrower label than Sanofi originally sought. Class context matters: fenebrutinib (Roche) had an FDA partial clinical hold in December 2023 after Hy's Law-consistent liver enzyme elevations and later reported at least one Hy's Law case in the Phase 3 FENhance program [18]. Evobrutinib (Merck KGaA) was discontinued in 2023 after negative Phase 3 in relapsing MS and had prior FDA liver holds. Remibrutinib (Novartis) cleared Phase 3 in relapsing MS with no reported liver safety signal to date [18][19], which suggests DILI is compound-specific across the class rather than a strict class effect, and is a competitive concern for tolebrutinib. Efficacy risk is bifurcated: nrSPMS is supported by HERCULES [1][15], but two of three registration studies missed, forcing Sanofi into a narrow indication rather than a broad MS franchise [6][7]. Commercial risk is real even with approval. Epidemiology puts SPMS at roughly 10 to 12% of the MS population, with non-relapsing SPMS estimated at approximately 7 to 9% of the total MS population depending on the criteria applied [20][21]. Against a US MS population of roughly 1 million, that implies a nrSPMS addressable pool in the range of 70,000 to 90,000 patients. Diagnostic criteria are not standardized in routine neurology practice, so real prescribing populations depend on how consistently clinicians and payers apply the HERCULES-style criteria; that friction sits on top of an already narrow indication. Execution risk is comparatively low given Sanofi's neurology commercial footprint, but CRL response strategy is the near-term determinant of the US timeline.

Worth watching closely. Tolebrutinib is the closest active bet on the microglia-driven progressive MS thesis, and nrSPMS is a genuine unmet need without approved options. Two key events since the original model score have already resolved: the FDA issued a CRL in December 2025 (negative for US path) and the European Commission approved Cenrifki on June 23, 2026 as the first disability-targeting therapy in nrSPMS (positive for EU path) [3][4][16]. What remains open is (1) the US resubmission strategy, since Sanofi has said it will continue dialogue with FDA to identify a favorable benefit-risk population but has not committed to a filing date [3]; (2) real-world uptake in Europe, which is a leading indicator for the addressable population and will directly inform US label negotiations; and (3) long-term safety from NCT06372145, since hepatic and infection tolerability over multi-year exposure will define the addressable population even in an approved market [8]. Sanofi's 2024 net sales of €41.1B (approximately $44.5B) provide ample cover to work through the CRL without financial stress [5], which reduces the risk of premature program termination. Read-through matters: EU approval of a first-in-class CNS-penetrant BTK inhibitor in progressive MS is a partial de-risking event for Roche's fenebrutinib and Novartis' remibrutinib, though remibrutinib's cleaner liver profile is the more relevant competitive read [18][19]. Not investment advice.